Diabetes

TrialNet is testing rituximab-pvvr and abatacept, one after the other, to learn if using both treatments extend insulin production in people (ages 8-45) who were newly diagnosed with type 1 diabetes (T1D). Each therapy has a history of safety and effectiveness. Rituximab-pvvr is FDA-approved to…

For people age 12 – 35 years who have been diagnosed with type 1 diabetes in the past 3 months, this study tests two JAK inhibitors (abrocitinib and ritlecitinib) to see if either or both can preserve insulin production. TrialNet researchers are testing two different…

One in five adolescents and young adults with type 1 diabetes exhibit disordered eating behaviors (DEB)—nearly twice the rate among healthy peers and affecting females more than males. Several studies show that those with DEB have worse health outcomes. Researchers at the Seattle Children’s Hospital…

In recent years a new group of medications to control blood sugar have been approved by the FDA. These “GLP1-RA” drugs have been proven to work well on lowering blood sugars and improving the health of patients with Type 2 Diabetes. Early data also indicates…

The EN 21-01 study is testing a new investigational medication, called NRD135S.E1, to see if it is helpful and safe for patients with painful diabetic peripheral neuropathy. NRD135S.E1 showed a decrease in pain after 3 weeks of study treatment when compared to a placebo in…

This research study is a collaboration between the University of Wyoming and the University of Washington. We are asking you to complete this survey because you are over the age of 65 years. The purpose of this survey is to better understand various health behaviors…

Identify patients and families with novel rare/atypical forms of diabetes and characterize the underlying molecular mechanisms Outreach and inclusivity of minority and underrepresented populations Perform genetic and phenotypic characterization of participants Construct an access-controlled biorepository and database Make data and biosamples available to the scientific…

The UW Medicine Diabetes Institute is the proud home of the COVERED Registry. COVERED stands for Community of Volunteers Engaged in Research to End Diabetes. The goal of this patient registry is to connect people interested in diabetes care with researchers studying diabetes and other…

We are inviting you to participate in a research study to help us improve our understanding of diabetes and immune mediated diseases. The study consists of a computer registry where we store your contact, research, and health information, and a sample repository where we keep…

TrialNet’s Pathway to Prevention studies the development of type 1 diabetes, and screens relatives of people with type 1 diabetes for their risk of developing the disease. Relatives of people with type 1 diabetes have about a 3 to 4 percent chance of being positive…